Levetiracetam (Keppra) is an adjunct therapy in the treatment of partial seizures in adults. Its mechanism of action is unknown; it does not act on sodium gated channels, or on GABA or glutamate receptors.
Samples for analysis should be taken pre-dose (trough levels).
Analysed by GC-MS
There is no evidence to justify monitoring of Levetiracetam other than to assess adherence, though a range of 6 – 20 mg/L has been suggested. Renal excretion means that the plasma half-life is longer in the elderly. Dose reduction is necessary at GFR < 60 mL/min/1.73 m2.
Copyright heftpathology 2013, 2014, 2015, 2016, 2017, 2018
HTA licence number is 12366
Protection of Personal Information – Laboratory Medicine comply with the Trust Data Protection Policy and have procedures in place to allow the Directorate and it’s employees to comply with the Data Protection Act 1998 and associated best practice and guidance.
The Trust Laboratories at Heartlands Hospital, Good Hope Hospital and Solihull Hospital were awarded UKAS (United Kingdom Accreditation Service) accreditation to the internationally recognised ISO 15189 standard in May 2015. For a list of accredited tests and other information please visit the test database http://www.heftpathology.com/frontpage/test-database.html.
Tests not appearing on this scope are either under consideration or in the process of accreditation and so currently remain outside of our scope of accreditation. However, these tests have been validated to the same high standard as accredited tests and are performed by the same trained and competent staff.
For further information contact Louise Fallon, Quality Manager, 0121 424 1235